ERBB2 and breast carcinoma: Notably, the monoclonal antibody trastuzumab and small molecule inhibitors of HER1/HER2/HER3 tyrosine kinases, such as lapatinib and neratinib, have transformed the care for patients with HER2-overexpressing breast cancer [5].